Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stanford Hospital also studying ECOR Gammacore - so they have units, are familiar with the technology, and will order more- like Northwell and Harvard system “Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines“
Trial ID or NCT#
NCT03716505
Recruiting
ECOR studied at Northwell-the 14th largest health system in the U.S. and the largest in New York, with 6,600 hospital and long-term care beds- in a single site, randomized, sham-controlled, double blinded pilot study assessing the feasibility, safety, tolerability, and efficacy of non-invasive VNS (nVNS), gammaCore, in the treatment of headache in subarachnoid hemorrhage (SAH). 40 participants will be enrolled, 20 in the active device arm and 20 in the sham arm. The primary efficacy outcome is the the difference between the active and sham treatment groups in morphine equivalence dosage. https://clinicaltrials.gov/ct2/show/NCT04126408 Their Depts of neurology already have units - will expand with broadening of Targets.
ECOR Gammacore unit in hand - learning this weekend - treating Monday -patients booked with insurance
Coverage and $100 copy. Let the ECOR revenue grow.
7/31/20 Is ECOR Gammacore day 1 in my medical practice - beginning patient education and recruitment for Gammacore treatment of cephalagia, but wont hesitate to treat COVID asthma as well. photo of my new unit posted on StockTwits. Reviews will be posted after each use.
ECOR on 8/11 - will report on 1st 2 wk Gammacore/refill sales- next leg up.
ECOR- The big profits are in the refills - the value of the PR isn’t the hardware price -this little company would be immediately profitable if they gave away the units and just sold prescription software over the phone - the $1250 is merely gravy - what the COVID market will bear. (Which will squeeze bears).
ECOR- the value of the PR isn’t the hardware price -this little company would be immediately profitable if they gave away the units and just sold prescription software over the phone - the $1250 is merely gravy - what the COVID market will bear. (Which will squeeze bears).
ECOR No waiting “electroCore is planning to establish a telehealth option for gammaCore Sapphire CV that will facilitate the immediate processing and fulfillment of a prescription and will provide that information as it becomes available.“ Each hospital unit will service multiple patients each day - call ECOR and Insurance Company is charged for treatment- register will be ringing regularly. Hardware+Software Play - paging PHG.
ECOR there is NO competition for early COVID - No therapeutics approved - not Avigan, Interferon Lambda, or Bemcentinib. I just received my Gammacore unit for migraine and will use it off label for Respiratory COVID should I or a family member become ill. Millions will use it off label until ARDS EUA in the fall- when upsurge in COVID expected.
You Can’t spell C-O-v-E-R without ECOR! COVID Cover coming- Hospital Order Revenue Starts Today.
ECOR COVID Revenue begins tomorrow AM.
ECOR is selling its COVID unit for $1250 per -2x Migraine price- Plus refills - up and running - as is AH price per share- at a Mkt cap of $58M while ALT has a P1 in Q4 - preclinical today at mkt cap of
$834M - What?
Enrollment in Spanish COVID Gammacore trial closes tomorrow.
ECOR -if electricity can treat Brain Cancer (NVCR) it can treat COVID.
On ECOR For COVID 19 Neuromodulation “We draw the conclusion that vagus nerve stimulation may be a supporting treatment in the therapy continuum of COVID-19 patients by combined modulation of respiratory function as well as the neuro-immune axis.” - Nonpharmacologic therapy additive to Lenzilumab, et. al. In COVD Pneumonia/ARDS
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368662/#__ffn_sectitle
ECOR - “gammaCore is not associated with any drug interactions and can be used several times within a 24-hour period with no multidose-related adverse effects (AEs). In the randomized, double-blind, sham-controlled ACT-1 and ACT-2 trials, gammaCore was superior to sham in rapidly aborting acute pain associated with episodic cluster headache and was well tolerated. 6 In PREVA, a prospective, multicenter, open-label, randomized controlled trial, gammaCore was also superior in reducing the number of attacks compared with controls in addition to being safe and well tolerated.“
https://scholar.google.com.hk/scholar?as_ylo=2020&q=gammacore&hl=en&as_sdt=0,33#d=gs_qabs&u=%23p%3DheYAMS8DVm4J
Yes these are Heady days for HGEN!
IL-6 Repurposing “Bites the Dust” 1 Day After HGEN Lenzilumab Chosen by NIH NIAID for same target.
https://endpts.com/roche-declares-a-phiii-failure-for-covid-19-as-the-il-6-repurposing-theory-bites-the-dust/
ECOR Reduces The Mental Stress of COVID 19 Infection by counterbalancing the Sympathetic ( fight or flight)
Nervous system -if it does nothing else to aid respiration (and early studies say it Does) - it will still be found useful in treating COVID 19, given its excellent safety record.
COVID Worsens PTSD- ECOR can help
https://www.ptsd.va.gov/covid/COVID_effects_ptsd.asp
https://www.medrxiv.org/content/10.1101/2020.02.10.20021626v3.full.pdf
On ECOR Gammacore Positive for PostTraumatic Stress
“Conclusion: tcVNS attenuates sympathetic arousal associated with stress related to traumatic memories as well as mental stress in patients with PTSD, with effects persisting throughout multiple traumatic stress and stimulation testing days. These findings show that tcVNS has
beneficial effects on the underlying neurophysiology of PTSD. Such autonomic metrics may also be evaluated in daily life settings in tandem with tcVNS therapy to provide closed-loop delivery and measure efficacy.” (Post Trumatic Stress)
https://www.medrxiv.org/content/10.1101/2020.02.10.20021626v3.full.pdf
On EIGR (Lambda is IFN III) “Treatment with type I and III IFNs can dramatically inhibit SARS-CoV-2 replication in primary human airway epithelial cells with the corresponding induction of ISGs.22 The role of type III IFNs in the suppression of virus replication has been highlighted.23,24 Type III IFN shows a better treatment option than type I IFN for influenza A virus-induced disease for its induction of antiviral immunity without the pro-inflammatory responses.”
https://www.biorxiv.org/content/10.1101/2020.07.26.222026v1.full.pdf
On ECOR “We draw the conclusion that vagus nerve stimulation may be a supporting treatment in the therapy continuum of COVID-19 patients by combined modulation of respiratory function as well as the neuro-immune axis.” - Nonpharmacologic therapy additive to Lenzilumab, et. al. In COVD Pneumonia/ARDS
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368662/#__ffn_sectitle
HGEN competition falling away - “Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia
COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoint of reduced patient mortality
The study is the first global, randomised, double-blind, placebo-controlled phase III trial investigating Actemra/RoActemra in this setting”
Well said - excellent points.
ECOR it just so happens the the Vagus nerve stimulation Gammacore provides reduces Trigeminal nerve firing https://journals.sagepub.com/doi/full/10.1177/0333102420941864 and “Almost all migraine sufferers have a problem with a specific part of the nervous system, called the trigeminal nerve. The trigeminal nerve is a network of wiring that attaches to special sensors.”
https://www.migrainedisorders.org › ...
PHG - ECOR - who else is going to bring the world Electrical treatment of COVID 19 and Migraine?
HGEN - 1/4 the Market Cap of CYDY with 4x the potential - per NIAID/NIH.
HGEN is Cytokine Blocking Cream Rising to the top as NIH passed on Roivant and CYDY.
HGEN singled out today by the NIH-NIAID over
$CYDY - Roivant - Izana as the Cytokine reduction with greatest likelihood of success- alone and with Remdesivir.
https://markets.ft.com/data/announce/detail?dockey=600-202007271605BIZWIRE_USPRX____BW5674-1
“We are thrilled that NIH selected lenzilumab to be part of its Big Effect Trial,” said Cameron Durrant, MD, MBA, chief executive officer of Humanigen. “With data from the BET and our ongoing Phase III study, we will have data from approximately 500 hospitalized COVID-19 patients.” Locked and loaded.
HGEN - “National Institutes of Health Selects Humanigen’s Lenzilumab for its COVID-19 Big Effect Trial
Big Effect Trial (BET) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) to advance high priority therapeutic candidates for COVID-19
Lenzilumab will be evaluated in combination with remdesivir and compared to placebo and remdesivir- “We are thrilled that NIH selected lenzilumab to be part of its Big Effect Trial,” said Cameron Durrant, MD, MBA, chief executive officer of Humanigen. “With data from the BET and our ongoing Phase III study, we will have data from approximately 500 hospitalized COVID-19 patients.” https://www.businesswire.com/news/home/20200727005674/en/National-Institutes-Health-Selects-Humanigen’s-Lenzilumab-COVID-19
ECOR COVID thesis newly supported by the Division of Functional and Stereotactic Neurosurgery at Univ of Bonn - a group that has no tie to the NJ company yet is more enthusiastic than any corporate PR :
https://www.sciencedirect.com/science/article/pii/S0306987720312615?via%3Dihub#!
ECOR - “Can neuromodulation support the fight against the COVID19 pandemic? “Transcutaneous non-invasive vagal nerve stimulation as a potential targeted treatment of fulminant ARDS” “we are providing this version to give early visibility of the article” “We draw the conclusion that vagus nerve stimulation may be a supporting treatment in the therapy continuum of COVID-19 patients by combined modulation of respiratory function as well as the neuro-immune axis.” From Stereotactic and Functional Neurosurgery, Department of Neurosurgery, University Hospital Bonn, Germany
Department of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368662/#__ffn_sectitle
Bigspirit - Migraines are important BUT a Worldwide Emergency in the form of
Viral induced Acute Respiratory Distress Syndrome is a more important target and the company that
Successfully treats it will have a green printing press.
EIGR “IFN-Lambda4 showed a strong therapeutic effect in reducing MERS-CoV infection with higher induction of IFN-stimulated genes. Thus, IFN-? has a decisive function in the respiratory epithelium that greatly limits MERS-CoV replication, and may be a key cytokine for better therapeutic outcomes against MERS-CoV infection in respiratory tract.” Success w/1 coronavirus is Promising-awaiting word from Stanford on interim dat in SARS-2 by summer’s end.
https://scholar.google.com/scholar?start=10&q=interferon+lambda&hl=en&as_sdt=0,33&as_ylo=2020#d=gs_qabs&u=%23p%3DG9p7gPGYVVwJ
HGEN - Univ of New Mexico Global Health COVID19 Briefing ” Small study shows benefit of lenzilumab in high risk patients with severe pneumonia
MedRxiv preprint: Hospitalized patients with COVID-19 pneumonia and risk factors for poor outcomes were treated with lenzilumab 600 mg intravenously for three doses through an emergency single-use IND - Clinical improvement was seen in 11/12 (92%) with significant improvement in oxygenation and a median 5 day discharge” https://digitalrepository.unm.edu/cgi/viewcontent.cgi?article=1050&=&context=hsc_covid19_briefings&=&sei-redir=1&referer=https%253A%252F%252Fscholar.google.com%252Fscholar%253Fas_ylo%253D2020%2526q%253DLenzilumab%2526hl%253Den%2526as_sdt%253D0%252C33%2523d%253Dgs_qabs%2526u%253D%252523p%25253D1F5RMpvTnwoJ#search=%22Lenzilumab%22
ECOR “The Dutch company, Philips already announced its plan to sell its domestic appliances business in 2021, and as per a report of Pulse, Samsung might be planning to take that division-Philips is actually trying to focus on the healthcare sector. As a result, it is on the way to sell the audio and video business as well as the lighting department.“ so a $250M acquistion of Gammacore would be a natural for this hardware only health care company.